{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:53:16Z","timestamp":1781578396490,"version":"3.54.5"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijid.2026.108736","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T23:31:22Z","timestamp":1777073482000},"page":"108736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Re: Petersen E, Hviid AP. Inosine pranobex as a treatment of SARS-CoV-2? Int J Infect Dis. 2026"],"prefix":"10.1016","volume":"169","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6284-8134","authenticated-orcid":false,"given":"Simon","family":"Reich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.108736_bib11","doi-asserted-by":"crossref","first-page":"108519","DOI":"10.1016\/j.ijid.2026.108519","article-title":"Inosine pranobex was associated with a reduction in mortality in COVID-19 by over 22%, as reported in a retrospective study utilizing complete health data from the Czech national registry","volume":"167","author":"Vesel\u00fd","year":"2026","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2026.108736_bib12","doi-asserted-by":"crossref","first-page":"108657","DOI":"10.1016\/j.ijid.2026.108657","article-title":"Inosine pranobex as a treatment of SARS-CoV2?","volume":"167","author":"Petersen","year":"2026","journal-title":"Int J Infect Dis"},{"issue":"10229","key":"10.1016\/j.ijid.2026.108736_bib0001","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ijid.2026.108736_bib0002","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/jcm9020538","article-title":"Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data","volume":"9","author":"Linton","year":"2020","journal-title":"J Clin Med"},{"issue":"172","key":"10.1016\/j.ijid.2026.108736_bib0003","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2020.0596","article-title":"Inference of COVID-19 epidemiological distributions from Brazilian hospital data","volume":"17","author":"Hawryluk","year":"2020","journal-title":"J R Soc Interface"},{"key":"10.1016\/j.ijid.2026.108736_bib0004","article-title":"Features of 20,133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study","volume":"369","author":"Docherty","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ijid.2026.108736_bib0005","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s11606-010-1609-1","article-title":"Healthy user and related biases in observational studies of preventive interventions: a primer for physicians","volume":"26","author":"Shrank","year":"2011","journal-title":"J Gen Intern Med"},{"issue":"4","key":"10.1016\/j.ijid.2026.108736_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106130","article-title":"Ivermectin for COVID-19 in adults in the community (PRINCIPLE): an open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes","volume":"88","author":"Hayward","year":"2024","journal-title":"J Infect"},{"issue":"11","key":"10.1016\/j.ijid.2026.108736_bib0007","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jama.2023.1650","article-title":"Effect of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in outpatients with COVID-19","volume":"329","author":"Naggie","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2026.108736_bib0008","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1056\/NEJMoa2115869","article-title":"Effect of early treatment with ivermectin among patients with COVID-19","volume":"386","author":"Reis","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ijid.2026.108736_bib0009","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1177\/009127002237994","article-title":"Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects","volume":"42","author":"Guzzo","year":"2002","journal-title":"J Clin Pharmacol"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226003711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226003711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:43:09Z","timestamp":1781577789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226003711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":11,"alternative-id":["S1201971226003711"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108736","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Petersen E, Hviid AP. Inosine pranobex as a treatment of SARS-CoV-2? Int J Infect Dis. 2026","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108736","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108657","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108736"}}